EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Vergleichsstudie

Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial

Chisato Izumi iD, Masashi Amano, Yusuke Yoshikawa iD, Satsuki Fukushima, Hitoshi Yaku, Kiyoyuki Eishi iD, Taichi Sakaguchi, Nobuhisa Ohno iD, Arudo Hiraoka iD, Kenji Okada, Yoshikatsu Saiki iD, Takashi Miura und 5 weitere

Circulation: Cardiovascular Interventions · 2025-07 · 18 (7)

DOI: 10.1161/circinterventions.124.015108 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2025-07. Verfasst von Chisato Izumi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Heart Failure and Transplantation (C.I., M.A.), National Cerebral and Cardiovascular Center, Suita, Japan. Hauptthemen laut MEDLINE: Bioprosthesis, Factor Xa Inhibitors, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anticoagulant therapy with vitamin K antagonists is recommended in the current guidelines for 3 to 6 months following bioprosthetic valve replacement. However, in the era of direct oral anticoagulants, there is a paucity of evidence regarding the efficacy and safety of direct oral anticoagulants in this patient group. METHODS: The ENBALV trial (Edoxaban in Anticoagulant Therapy After Surgical Bioprosthetic Valve Replacement) was an investigator-initiated, phase 3, randomized, open-label, multicenter study that aimed to evaluate the efficacy and safety of edoxaban compared with warfarin within 3 months following bioprosthetic valve replacement at the aortic or mitral position or both. The primary outcome was stroke or systemic embolism. The secondary outcomes included major bleeding, intracardiac thrombus, and a composite of stroke, systemic embolism, or major bleeding. Given the limited study period and the low event rate of the primary outcome, this study assessed the difference in the point estimates of the event rate. RESULTS: Of the 410 enrolled patients, 389 were included in the final analysis (73±6 years, 56.8% male, 79.4% sinus rhythm; edoxaban group: n=195, warfarin group: n=194). The primary outcome occurred in 0.5% (n=1) in the edoxaban group, whereas in 1.5% (n=3) in the warfarin group (risk difference, −1.03% [95% CI, −4.34 to 1.95%]). Major bleeding occurred in 4.1% (n=8) in the edoxaban group and in 1.0% (n=2) in the warfarin group (risk difference, 3.07% [95% CI, −0.67 to 7.27%]). No fatal bleeding or intracranial hemorrhage was observed in patients treated with edoxaban, whereas 1 fatal intracranial hemorrhage occurred in the warfarin group. Intracardiac thrombus did not occur in any of the patients in the edoxaban group, but did occur in 1.0% (n=2) in the warfarin group. CONCLUSIONS: Edoxaban is a potential alternative anticoagulant therapy early after bioprosthetic valve replacement. REGISTRATION: URL: https://jrct.niph.go.jp/latest-detail/jRCT2051210209 ; Unique identifier: jRCT2051210209.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BioprosthesisFactor Xa InhibitorsHeart Valve ProsthesisHeart Valve Prosthesis ImplantationPyridinesThiazolesAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, OralAnticoagulantsAortic ValveEmbolismHemorrhageMitral ValveProsthesis DesignRisk FactorsStrokeThrombosisTime FactorsTreatment OutcomeWarfarin

Stichwörter der Autor:innen

anticoagulantsbioprosthesisedoxabanhemorrhagestrokethrombosis

Substanzen

AnticoagulantsedoxabanFactor Xa InhibitorsPyridinesThiazolesWarfarin

Autor:innen und Institutionen

  • Department of Heart Failure and Transplantation (C.I., M.A.), National Cerebral and Cardiovascular Center, Suita, Japan.
  • Department of Biostatistics (Y.Y.), National Cerebral and Cardiovascular Center, Suita, Japan.
  • Department of Cardiovascular Surgery (S.F.), National Cerebral and Cardiovascular Center, Suita, Japan.
  • Department of Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Japan (H. Yaku).
  • Department of Cardiovascular Surgery, Hakujyuji Hospital, Fukuoka, Japan (K.E.).
  • Department of Cardiovascular Surgery, Hyogo Medical University, Nishinomiya, Japan (T.S.).

ORCID-Profile: Chisato Izumi, Yusuke Yoshikawa, Kiyoyuki Eishi, Nobuhisa Ohno, Arudo Hiraoka, Yoshikatsu Saiki, Haruko Yamamoto, Katsuhiro Omae

Zitieren

APA

Izumi, C., Amano, M., Yoshikawa, Y., Fukushima, S., Yaku, H., Eishi, K., Sakaguchi, T., Ohno, N., Hiraoka, A., Okada, K., Saiki, Y., Miura, T., Komiya, T., Minami, M., Yamamoto, H., Omae, K., & ENBALV Trial Investigators (2025). Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial. Circulation: Cardiovascular Interventions, 18(7). https://doi.org/10.1161/circinterventions.124.015108

Vancouver

Izumi C, Amano M, Yoshikawa Y, Fukushima S, Yaku H, Eishi K, et al. Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial. Circulation: Cardiovascular Interventions. 2025;18(7). doi:10.1161/circinterventions.124.015108

BibTeX
@article{Izumi2025,
  author = {Izumi, Chisato and Amano, Masashi and Yoshikawa, Yusuke and Fukushima, Satsuki and Yaku, Hitoshi and Eishi, Kiyoyuki and Sakaguchi, Taichi and Ohno, Nobuhisa and Hiraoka, Arudo and Okada, Kenji and Saiki, Yoshikatsu and Miura, Takashi and Komiya, Tatsuhiko and Minami, Manabu and Yamamoto, Haruko and Omae, Katsuhiro and ENBALV Trial Investigators, ENBALV Trial Investigators},
  title = {Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {7},
  doi = {10.1161/circinterventions.124.015108}
}
Kostenlos starten →